Cao M González, Auge J M, Molina R, Martí R, Carrera C, Castel T, Vilella R, Conill C, Sánchez M, Malvehy J, Puig S
Medical Oncology Department, Institut Clinic de Malaties Hematologiques i Oncològiques (ICMHO).
Anticancer Res. 2007 Jan-Feb;27(1B):595-9.
Serum levels of melanoma markers may have a role in monitoring disease evolution in metastatic melanoma.
Serial measurements of melanoma inhibiting activity protein (MIA), lactate dehydrogenase (LDH), S-100 and beta2-microglubulin were obtained from 42 metastatic melanoma patients during their biochemotherapy treatment.
High pre-treatment serum levels of S-100, LDH, MIA and P2-microglobulin were detected in 50%, 57%, 50% and 24% of the patients, respectively. Only S-100 had prognostic significance for both disease-free (p=0.011) and overall survival (p=0.021). In patients who responded to treatment, S-100 levels decreased significantly from pre-treatment to the time of response (p = 0.050). When patients progressed, levels of MIA and P2-microglobulin increased significantly (p =0.028 and p =0.030, respectively).
Correlation with disease evolution was found for S-100, MIA and P2-microglobulin levels. Despite the small sample size of the study, S-100 was a significant prognostic marker for overall survival and disease-free survival.
黑色素瘤标志物的血清水平可能在监测转移性黑色素瘤疾病进展中发挥作用。
在42例转移性黑色素瘤患者接受生物化疗期间，对黑色素瘤抑制活性蛋白（MIA）、乳酸脱氢酶（LDH）、S-100和β2-微球蛋白进行了连续测量。
分别在50%、57%、50%和24%的患者中检测到治疗前血清S-100、LDH、MIA和P2-微球蛋白水平较高。只有S-100对无病生存期（p=0.011）和总生存期（p=0.021）均具有预后意义。在对治疗有反应的患者中，S-100水平从治疗前到出现反应时显著下降（p = 0.050）。当患者病情进展时，MIA和P2-微球蛋白水平显著升高（分别为p =0.028和p =0.030）。
发现S-100、MIA和P2-微球蛋白水平与疾病进展相关。尽管该研究样本量较小，但S-100是总生存期和无病生存期的重要预后标志物。
